NASHVILLE, Tenn., April 24, 2018 -- Aegis Sciences Corporation, a leading healthcare sciences and forensic toxicology laboratory, is pleased to announce that Dr. Elaine Jeter has joined the company as its Senior Medical Policy Advisor.
“I am delighted to welcome Dr. Elaine Jeter,” said Dr. Frank Basile, Aegis’s Chief Executive Officer. “Dr. Jeter’s wealth of experience in clinical medicine and Medicare will be very valuable to Aegis.”
As Senior Medical Policy Advisor, Dr. Jeter will assist with both regulatory and medical coverage policy engagement and compliance, new and existing Managed Care relationships, and development of appropriate evidence-based clinical utility evidence for Aegis’s new and innovative testing services.
In regards to her decision to serve as Aegis’s Senior Medical Policy Advisor, Dr. Jeter said, “I am excited to join the Aegis team in this critical role as it has and continues to maintain a pristine track record for quality, compliance and integrity in toxicology testing, which is manifest at all levels within the organization.”
Prior to joining Aegis, Dr. Jeter was the Senior Medical Director at Palmetto GBA, a Medicare Administrative Contractor that administers Medicare health insurance for the Centers for Medicare & Medicaid Services (CMS) throughout the U.S. At Palmetto GBA, Dr. Jeter developed and directed the MolDX program, which was created to uniquely identify laboratory tests, primarily sole-source and molecular tests, and to determine the clinical value of a test by way of a technical assessment. The assessments were subsequently developed into Medicare local coverage decision policies. In the field of toxicology, her “Controlled Substance Monitoring and Drugs of Abuse Testing” coverage policy has largely become the model across the country for providers and payers alike.
Dr. Jeter has practiced surgical pathology and directed clinical laboratories in academia and the private practice. She completed her medical school and residency training at the Medical University of South Carolina (MUSC) in Charleston, SC. She is board certified in Anatomic and Clinical Pathology, with sub-specialty boards in Blood Banking and Transfusion Medicine.
About Aegis Sciences Corporation
Founded in 1990, Aegis Sciences Corporation is a laboratory sciences company based in Nashville, TN, that provides science-driven testing and consulting services for clients such as healthcare providers, pharmaceutical companies, professional and amateur sports organizations, leading college and university athletic programs, Fortune 500 corporations, and government agencies throughout the United States. For more information please visit http://www.aegislabs.com/
Contact:
Stephanie Protz, Manager, Marketing Communications
[email protected]
615-577-4535


T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality
Capital One Says AML Review Led to Closure of Trump Organization Accounts
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit
Japan Earthquake Disrupts Auto and Chip Supply Chains
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 



